Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2024-10-17 Interim / Quarterly Rep…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period 'Januari – September 2024'. It contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business performance, clinical pipeline updates, and commercial activities. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-10-17 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' and covers the period 'January – September 2024'. It contains detailed financial statements, including a 'Financial Summary' table with unaudited figures for Q3 2024 and 9M 2024, as well as comprehensive management commentary on business performance, clinical trials, and financial results. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2024
2024-10-17 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halvårsrapport' (Half-year report) for the period January–June 2024. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet items, as well as detailed management commentary on business performance, clinical pipeline updates, and financial results. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2024
2024-07-18 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Year Report' for the period 'January – June 2024'. It contains comprehensive financial statements, including revenue, expenses, loss for the period, and cash flow data, as well as detailed business and clinical pipeline updates. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year. H2 2024
2024-07-18 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in the shareholding percentage of 'Redmile Group, LLC' in 'Hansa Biopharma AB'. It explicitly uses the term 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, culminating in a 'Resulting distribution of total holdings'. This structure is characteristic of a notification regarding a significant change in ownership, which corresponds to the Major Shareholding Notification category (MRQ). The document is a direct notification, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2024-07-02 English
Hansa Biopharma: increase in number of shares and votes
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release from Hansa Biopharma announcing an 'increase in number of shares and votes' due to the issuance of new ordinary shares and the conversion of class C shares. This directly relates to changes in the company's capital structure, specifically the total number of shares outstanding. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2024-06-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.